| GC-MS SpectraSpectrum Type | Description | Splash Key | Deposition Date | Source | View |
---|
Predicted GC-MS | Predicted GC-MS Spectrum - Oltipraz GC-MS (Non-derivatized) - 70eV, Positive | splash10-0fi1-4920000000-60677f0b7b091bb6734c | 2017-08-28 | Wishart Lab | View Spectrum | Predicted GC-MS | Predicted GC-MS Spectrum - Oltipraz GC-MS (Non-derivatized) - 70eV, Positive | Not Available | 2021-10-12 | Wishart Lab | View Spectrum | Predicted GC-MS | Predicted GC-MS Spectrum - Oltipraz GC-MS (Non-derivatized) - 70eV, Positive | Not Available | 2021-10-12 | Wishart Lab | View Spectrum |
MS/MS SpectraSpectrum Type | Description | Splash Key | Deposition Date | Source | View |
---|
Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Oltipraz 10V, Positive-QTOF | splash10-004i-0090000000-ce9c1a622423f007c109 | 2017-07-26 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Oltipraz 20V, Positive-QTOF | splash10-004i-0490000000-414672cb986fd0c578cc | 2017-07-26 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Oltipraz 40V, Positive-QTOF | splash10-0fkd-9800000000-9f859ae312457f0c2610 | 2017-07-26 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Oltipraz 10V, Negative-QTOF | splash10-00di-0190000000-c9e3929f1beb5f243d2d | 2017-07-26 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Oltipraz 20V, Negative-QTOF | splash10-00di-1490000000-d8175cb11a75030c94ee | 2017-07-26 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Oltipraz 40V, Negative-QTOF | splash10-0002-6900000000-861554ece86b44d43e7f | 2017-07-26 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Oltipraz 10V, Positive-QTOF | splash10-004i-0090000000-1a6fef210add2aae025c | 2021-09-23 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Oltipraz 20V, Positive-QTOF | splash10-004i-0090000000-1a6fef210add2aae025c | 2021-09-23 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Oltipraz 40V, Positive-QTOF | splash10-00kb-3900000000-8e3302f2a22a875f6060 | 2021-09-23 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Oltipraz 10V, Negative-QTOF | splash10-00di-0090000000-4d615ab1c3fe793fa09f | 2021-09-25 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Oltipraz 20V, Negative-QTOF | splash10-00di-0290000000-f44a0b79c3c9527a6d57 | 2021-09-25 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Oltipraz 40V, Negative-QTOF | splash10-00di-4900000000-eb378d09e2b309a63a83 | 2021-09-25 | Wishart Lab | View Spectrum |
| Show more...
---|
General References | - Piton A, Rauch C, Langouet S, Guillouzo A, Morel F: Involvement of pregnane X receptor in the regulation of CYP2B6 gene expression by oltipraz in human hepatocytes. Toxicol In Vitro. 2010 Mar;24(2):452-9. doi: 10.1016/j.tiv.2009.09.025. Epub 2009 Oct 12. [PubMed:19833192 ]
- Kim SG, Kim YM, Choi YH, Lee MG, Choi JY, Han JY, Cho SH, Jang JW, Um SH, Chon CY, Lee DH, Jang JJ, Yu ES, Lee YS: Pharmacokinetics of oltipraz and its major metabolite (RM) in patients with liver fibrosis or cirrhosis: relationship with suppression of circulating TGF-beta1. Clin Pharmacol Ther. 2010 Sep;88(3):360-8. doi: 10.1038/clpt.2010.89. Epub 2010 Jul 21. [PubMed:20664537 ]
- Kim SG, Kim YM, Choi JY, Han JY, Jang JW, Cho SH, Um SH, Chon CY, Lee DH, Jang JJ, Yu E, Lee YS: Oltipraz therapy in patients with liver fibrosis or cirrhosis: a randomized, double-blind, placebo-controlled phase II trial. J Pharm Pharmacol. 2011 May;63(5):627-35. doi: 10.1111/j.2042-7158.2011.01259.x. Epub 2011 Mar 14. [PubMed:21492164 ]
- Aqil F, Jeyabalan J, Kausar H, Bansal SS, Sharma RJ, Singh IP, Vadhanam MV, Gupta RC: Multi-layer polymeric implants for sustained release of chemopreventives. Cancer Lett. 2012 Dec 29;326(1):33-40. doi: 10.1016/j.canlet.2012.07.017. Epub 2012 Jul 20. [PubMed:22820161 ]
- Eba S, Hoshikawa Y, Moriguchi T, Mitsuishi Y, Satoh H, Ishida K, Watanabe T, Shimizu T, Shimokawa H, Okada Y, Yamamoto M, Kondo T: The nuclear factor erythroid 2-related factor 2 activator oltipraz attenuates chronic hypoxia-induced cardiopulmonary alterations in mice. Am J Respir Cell Mol Biol. 2013 Aug;49(2):324-33. doi: 10.1165/rcmb.2011-0396OC. [PubMed:23590302 ]
- Shimozono R, Asaoka Y, Yoshizawa Y, Aoki T, Noda H, Yamada M, Kaino M, Mochizuki H: Nrf2 activators attenuate the progression of nonalcoholic steatohepatitis-related fibrosis in a dietary rat model. Mol Pharmacol. 2013 Jul;84(1):62-70. doi: 10.1124/mol.112.084269. Epub 2013 Apr 16. [PubMed:23592516 ]
- Cerf P, Moyroud J, Coulanges P: [The treatment of Schistosomiasis mansoni with RP 35972 (Oltipraz). Preliminary results (author's transl)]. Bull Soc Pathol Exot Filiales. 1982 Mar-Apr;75(2):174-8. [PubMed:7105289 ]
- Benson AB 3rd: Oltipraz: a laboratory and clinical review. J Cell Biochem Suppl. 1993;17F:278-91. [PubMed:8412206 ]
| Show more...
---|